In addition, telmisartan – ARB – treatment was shown to inhibit tumour growth, invasion, and migration in NSCLC, and to activate NSCLC apoptosis through inhibition of the PI3K/AKT signalling pathway (112). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.